Citigroup
AGMB

Citigroup’s AgomAb Therapeutics NV AGMB Stock Holding History

Citigroup’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
+9,496
New +$107K ﹤0.01% 4567

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citigroup's AGMB Position: Q2 2026 in Review

Citigroup opened a new position in AgomAb Therapeutics NV (AGMB) in Q2 2026: 9,496 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #4567 among its holdings.

34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Citigroup held 9,496 shares of AgomAb Therapeutics NV worth $123K as of Q2 2026.
  • AgomAb Therapeutics NV was a new Citigroup position in Q2 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4567 holding.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.